Factory-Direct Peptide Manufacturer | GLP-1 & Retatrutide Bulk Supply

At ShiLai™ Peptide Technologies, we are a direct manufacturer of Retatrutide, offering high-purity GLP-1-based peptide compounds for pharmaceutical research and commercial supply. As a peptide factory with in-house production capabilities, we ensure consistent quality, competitive pricing, and reliable global delivery.
Retatrutide is a next-generation GLP-1/GIP/glucagon receptor agonist showing exceptional promise in the treatment of obesity, type 2 diabetes, and metabolic disorders. Our production process follows strict GMP-like quality controls and is suitable for preclinical studies, formulation development, and B2B supply.
We serve biotech companies, CROs, academic institutions, and international pharmaceutical buyers seeking trusted access to bulk Retatrutide and other therapeutic peptides
ShiLai™ Peptide Technologies is a professional peptide manufacturer specializing in the production and global supply of GLP-1 receptor agonists. As a factory-based supplier, we offer high-purity GLP-1 analogues for pharmaceutical R&D, formulation development, and commercial use — with full in-house synthesis and quality control.
Our facility produces a wide range of GLP-1-based peptides, including key compounds such as Semaglutide, Liraglutide, Tirzepatide, and Retatrutide, serving clients in diabetes research, obesity treatment, and metabolic drug discovery.
With years of experience in custom peptide synthesis, bulk manufacturing, and international export logistics, ShiLai™ is your trusted B2B partner for GLP-1 peptide solutions.
Peptides for Various Applications:
Whether you're a pharmaceutical distributor, clinic, or research team, we're here to help.
✅ Fast Response | ✅ Verified Suppliers | ✅ Global Shipping
Get in touch now — our experts are ready to assist you.
ShiLai™Peptide Technologies
Copyright © 2025 ShiLai™Peptide Technologies - All Rights Reserved.
ShiLai™
ShiLai™ Peptide Technologies supplies peptides solely for laboratory research and industrial R&D. We do not support or condone any unauthorized or off-label use